Table 2. Univariate analyses to assess individual potential prognostic factors with respect to overall survival following chemotherapy.
| |
|
Neoadjuvant chemotherapy |
First-line chemotherapy | ||
|---|---|---|---|---|---|
| Factor | Division | Median OS, years (95% CI) | P-value | Median OS, years (95% CI) | P-value |
| Age | ⩽70 | NR | 0.08 | 1.13 (0.66–1.61) | 0.21 |
| |
>70 |
3.36 (0.91–5.81) |
|
0.98 (0.68–1.30) |
|
| Sex | Male | 5.26 (4.37–6.15) | 0.49 | 1.16 (0.79–1.53) | 0.84 |
| |
Female |
4.05 (0.88–7.23) |
|
1.02 (0.71–1.33) |
|
| ECOG PS | 0 or 1 | 5.26 (4.52–6.01) | 0.000008 | 1.49 (1.08–1.90) | 0.0000005 |
| |
⩾2 |
0.42 (0.33–0.50) |
|
0.63 (0.47–0.79) |
|
| Hb | ⩾LLN | NR | 0.00005 | 1.39 (0.97–1.82) | 0.15 |
| |
<LLN |
1.22 (0.94–1.51) |
|
0.96 (0.69–1.24) |
|
| ALP | ⩽ULN | NR | 0.08 | 1.35 (1.05–1.65) | 0.003 |
| |
>ULN |
1.14 (0.87–1.41) |
|
0.66 (0.52–0.80) |
|
| LDH | ⩽ULN | 4.27 (0.10–8.44) | 0.34 | 1.23 (0.80–1.66) | 0.58 |
| |
>ULN |
NR |
|
1.04 (0.53–1.55) |
|
| Grade | 2 | 4.05 (2.71–5.40) | 0.90 | 1.02 (0.44–1.90) | 0.87 |
| |
3 |
5.26 (4.49–6.03) |
|
1.14 (0.87–1.41) |
|
| Primary tumour site | Bladder | — | 1.07 (0.78–1.35) | 0.57 | |
| |
Other |
— |
|
1.07 (0.66–1.49) |
|
| T stage | ⩽2 | NR | 0.006 | — | |
| 3 | 5.27 (4.15–6.39) | — | |||
| |
4 |
1.09 (0.61–1.57) |
|
— |
|
| Visceral metastases | No | — | 1.49 (1.03–1.95) | 0.004 | |
| |
Yes |
— |
|
0.78 (0.67–0.88) |
|
| Chemotherapy regimen | GC | NR | 0.001 | 1.49 (1.05–1.93) | 0.00005 |
| GCarbo | 0.89 (0.48–1.31) | 0.80 (0.41–1.20) | |||
| |
Other |
— |
|
0.57 (0.40–0.74) |
|
| Bajorin risk factors (Bajorin et al, 1999) | 0 | — | 1.74 (1.41–2.08) | 0.0000001 | |
| 1 | — | 0.98 (0.78–1.17) | |||
| |
2 |
— |
|
0.47 (0.31–0.65) |
|
| Prior perioperative chemotherapy | No | — | 1.15 (0.90–1.41) | 0.001 | |
| |
Yes |
— |
|
0.60 (0.50–0.70) |
|
| hCGβ level before chemotherapy | <2 IU l−1 | NR | 0.001 | 1.53 (1.17–1.89) | 0.04 |
| |
⩾2 IU l−1 |
1.86 (0.51–3.21) |
|
0.86 (0.67–1.05) |
|
| hCGβ level on completion of chemotherapy | <2 IU l−1 | 4.27 (1.65–6.89) | 0.000002 | 1.68 (1.25–2.11) | 0.00005 |
| ⩾2 IU l−1 | 0.42 (0.14–0.70) | 0.84 (0.68–1.00) | |||
Abbreviations: ALP=alkaline phosphatase; CI=confidence interval; ECOG PS=Eastern Cooperative Oncology Group performance status; GC=gemcitabine/cisplatin; GCarbo=gemcitabine/carboplatin; Hb=haemoglobin; LDH=lactate dehydrogenase; LLN=lower limit of normal for the treating institution's reference range; NR=not reached; ULN=upper limit of normal for the treating institution's reference range.